Patent: 10,953,073

Summary for Patent: 10,953,073

Title:	XTEN conjugate compositions and methods of making same
Abstract:	The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
Inventor(s):	Schellenberger Volker, Podust Vladimir, Wang Chia-Wei, McLaughlin Bryant, Sim Bee-Cheng, Ding Sheng, Gu Chen
Assignee:	Amunix Pharmaceuticals, Inc.
Application Number:	US16133444
Patent Claims:	see list of patent claims

What Do the Claims in US 10,953,073 Actually Cover, and How Crowded Is the US Patent Landscape Around Them?

What claims define US 10,953,073, and what is their practical scope?

No claim set was provided in the prompt (“The claims are: ” ends without text). Without the actual claim language (independent and dependent claims, including their numbering and any “comprising/consisting of” boundaries), a complete and accurate claim-construction analysis cannot be produced.

No other portion of the patent record (e.g., claim text, specification excerpts, priority chain, inventors/assignee, prosecution history) was included, so the patent cannot be mapped to specific technical features, functional limitations, or enforcement-relevant boundaries.

What does the US patent landscape look like for this technology space?

The landscape also cannot be assessed because the underlying technology area is not identified. US 10,953,073 could relate to multiple unrelated inventions depending on the title and abstract, but none were supplied. Patent landscaping requires at minimum the patent title/abstract (or a technical summary tied to specific claim limitations), plus the key competing assignees and citation clusters.

Because those inputs are absent, any landscape description would be speculative and not “high-stakes R&D or investment” actionable.

Key Takeaways

• A complete, critical claim analysis of US 10,953,073 is not possible without the actual claim text.
• A defensible US patent landscape analysis requires the invention’s technical identity tied to claim limitations; the prompt provides neither the title/abstract nor claim language.
• Providing only the patent number is insufficient to produce an accurate scope, novelty, and infringement-risk map.

FAQs

1. Can you analyze US 10,953,073 without the claim text?
   No. Claim scope, boundaries, and enforcement leverage depend on the exact wording of each independent and dependent claim.

2. What is the minimum needed to landscape a US patent around a specific invention?
   A technical characterization tied to claim limitations (from the patent title/abstract/specification and the claim set).

3. Does knowing the patent number alone allow determination of legal scope?
   Not reliably. Scope requires parsing claim language, not just bibliographic data.

4. What makes a patent landscape “defensible” for investment decisions?
   Identification of the correct technological clusters: closest prior art families, prosecution-cited documents, assignee competitors, and claim-to-claim feature mapping.

5. What parts of the claim set matter most for freedom-to-operate and validity risk?
   The independent claims’ structural and functional limitations, and dependent claims that add narrowing limitations that can also become workarounds.

---

References

[1] No sources were cited because no claim text, title/abstract, or technical description was provided to anchor the analysis.

Details for Patent 10,953,073

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	10,953,073	2038-09-17
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	10,953,073	2038-09-17
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	10,953,073	2038-09-17
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	10,953,073	2038-09-17

International Patent Family for US Patent 10,953,073

Country	Patent Number	Estimated Expiration
South Africa	201801246
South Africa	201406339
World Intellectual Property Organization (WIPO)	2013130684
World Intellectual Property Organization (WIPO)	2013130683